Compare DexCom, Inc. (DXCM) vs W W Grainger Inc (GWW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs W W Grainger Inc — how do they compare? DexCom, Inc. trades at $83.9 (market cap $31.86B), while W W Grainger Inc trades at $1,290.05 (market cap $59.76B). The key difference: W W Grainger Inc is the larger of the two by market cap, and W W Grainger Inc pays a 0.79% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and W W Grainger Inc for 25 Days on average.
| DXCM | GWW | |
|---|---|---|
Market Cap | $31.86B | $59.76B |
Volume | 3,607,070 | 186,697 |
Sector | Health | Industrials |
52-Week High | $92.34 | $1.40K |
52-Week Low | $54.84 | $918.18 |
Typical Hold Time | 62 Days | 25 Days |
Enterprise Value | $31.32B | $61.96B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
W.W. Grainger (GWW) trades at $1,263.51, down 0.94% on the day, amid a bearish technical signal. Recent earnings show mixed results with Q4 2025 missing estimates but Q1 and Q2 2026 beating expectations. The company maintains strong profitability with a net income margin of 9.92% and ROE of 47.92%, though valuation ratios like P/E of 32.34 appear elevated. Recent news highlights institutional buying and expansion efforts, including a new distribution center in Oregon and the acquisition of technology assets from Adroit Worldwide Media.
The outlook for GWW is cautiously optimistic, supported by earnings beats and solid fundamentals, but risks include high valuation and competitive pressures. Analyst consensus leans hold with a $1,310 price target, suggesting limited upside. Investors should weigh strong cash flow and dividend consistency against potential margin compression and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →
